Literature DB >> 23943252

NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism.

Francesca Pizzolo1, Francesco Zorzi, Laura Chiecchi, Letizia Consoli, Irene Aprili, Patrizia Guarini, Annalisa Castagna, Gian Luca Salvagno, Chiara Pavan, Oliviero Olivieri.   

Abstract

Primary aldosteronism (PA) is the most frequent form of secondary hypertension, but diagnostic tools for this disease still lack optimal accuracy. The heart is one important target tissue for damage due to excess aldosterone, and the role of natriuretic peptides is well recognized in diagnosing heart failure. We hypothesized that measuring the NT-proBNP could improve the diagnostic evaluation of PA. We enrolled 132 hypertensive patients, who underwent aldosterone to renin ratio (ARR) screening, and 81 underwent an intravenous saline loading test (ivSLT) because of a high ARR. The NT-proBNP level positively correlated with the ARR and inversely correlated with the renin level. The NT-proBNP level was higher in patients with a high ARR than in those with a low ARR and higher in patients with a positive ivSLT than in those with a negative ivSLT. After logistic regression analysis, an NT-proBNP value above the median and male gender were predictors of a positive ivSLT. The proportion of patients with a positive ivSLT ranged from only 23 % in females with a low NT-proBNP to 93 % in males with a high NT-proBNP. NT-proBNP and gender are predictors of a positive PA confirmatory test. These findings highlight the possibility of using NT-proBNP to identify which patients with a high ARR should receive a complete PA diagnostic evaluation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23943252     DOI: 10.1007/s12020-013-0028-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  36 in total

1.  Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.

Authors:  B J Gallay; S Ahmad; L Xu; B Toivola; R C Davidson
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Inappropriate left ventricular mass in patients with primary aldosteronism.

Authors:  Maria Lorenza Muiesan; Massimo Salvetti; Anna Paini; Claudia Agabiti-Rosei; Cristina Monteduro; Gloria Galbassini; Eugenia Belotti; Carlo Aggiusti; Damiano Rizzoni; Maurizio Castellano; Enrico Agabiti-Rosei
Journal:  Hypertension       Date:  2008-07-21       Impact factor: 10.190

4.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Franco Veglio; Chiara Bertello; Nicoletta Sonino; Paolo Della Mea; Mario Ermani; Franco Rabbia; Giovanni Federspil; Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

5.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

Review 6.  Primary aldosteronism: from bench to bedside.

Authors:  Norlela Sukor
Journal:  Endocrine       Date:  2011-11-01       Impact factor: 3.633

7.  Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity.

Authors:  Gary L Schwartz; Stephen T Turner
Journal:  Clin Chem       Date:  2005-02       Impact factor: 8.327

8.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

Review 9.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

10.  Update in primary aldosteronism.

Authors:  Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2009-09-08       Impact factor: 5.958

View more
  5 in total

1.  Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism.

Authors:  Wei Hu; Pang-hu Zhou; Xiao-bin Zhang; Chang-geng Xu; Wei Wang
Journal:  Endocrine       Date:  2014-06-11       Impact factor: 3.633

Review 2.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

3.  Fully automated chemiluminescence vs RIA aldosterone assay in primary aldosteronism work-up.

Authors:  F Pizzolo; G Salvagno; B Caruso; C Cocco; F Zorzi; C Zaltron; A Castagna; L Bertolone; F Morandini; G Lippi; O Olivieri
Journal:  J Hum Hypertens       Date:  2017-08-24       Impact factor: 3.012

4.  Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism.

Authors:  Qihong Wu; Mona Hong; Jianzhong Xu; Xiaofeng Tang; Limin Zhu; Pingjin Gao; Jiguang Wang
Journal:  Endocrine       Date:  2021-01-21       Impact factor: 3.633

5.  Abnormal gel flotation caused by contrast media during adrenal vein sampling.

Authors:  Gabriel Lima-Oliveira; Giuseppe Lippi; Gian Luca Salvagno; Matteo Gelati; Antonella Bassi; Alberto Contro; Francesca Pizzolo; Gian Cesare Guidi
Journal:  Biochem Med (Zagreb)       Date:  2016-10-15       Impact factor: 2.313

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.